Merja Soilu-Hänninen
MD, PhD
Turku University Hospital, Division of Clinical Neurosciences mersoi@utu.fi |
Clinical neurology; neuroimmunology; multiple sclerosis risk factors, prognostic factors and treatment
MD, University of Turku 1988
PhD, University of Turku, Department of Virology, Immunobiology of central nervous system virus infections 1996
Postdoctoral Fellow, Development and Neurobiology Group, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 1997-1999
Specialist Degree in Neurology 2001
Adjuct Professor of Clinical Neurology 2008
Inverstigator in several clinical MS trials
Chair of the Finnish MS registry 2016-
General Neurology Section Head, Turku University Hospital, Division of Clinical Neurosciences 2017-
Multiple sclerosis risk factors, prognostic factors and epidemiology.
Imaging of brain atrophy in multiple sclerosis.
Course of medical pedagogics 2011-2012
Supervisor of several PhD student
1 of 4
- Evaluation of patient-perceived fatigue in multiple sclerosis utilizing the Finnish MS registry (2025)
- Multiple Sclerosis Journal - Experimental, Translational and Clinical
- Evolving Patterns of Initial RRMS Treatment in Finland (2013–2022): Insights From a Nationwide Multiple Sclerosis Register (2025)
- Brain and Behavior
- Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria—a nationwide population-based registry study over five decades (2025)
- Multiple Sclerosis Journal - Experimental, Translational and Clinical
- Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study (2025)
- Journal of Neurology
- Patient Generated Digital Health Data: An Example from the Finnish Neuro Registry (2025)
- Studies in Health Technology and Informatics
- Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study (2024)
- Clinical Epidemiology
- Mortality and causes of death among Finnish patients with Multiple Sclerosis (2024)
- Multiple Sclerosis
- MS-tauti - Käypä hoito -suositus (2024) MS-tauti - Käypä hoito -suositus Kuusisto, Hanna; Laakso, Sini; Aartola, Jutta; Atula, Sari; Hartikainen, Päivi; Nuotio, Krista; Ryytty, Mervi; Saarinen, Jukka; Soilu-Hänninen, Merja
- MyMS: An Interface for Patient-Reported Outcomes for Finnish Individuals With Multiple Sclerosis (2024)
- International journal of MS care
- Exposure to systemic antibiotics in outpatient care and the risk of multiple sclerosis (2023)
- Multiple Sclerosis
- Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers (2023)
- Multiple Sclerosis Journal - Experimental, Translational and Clinical
- Real-world treatment outcomes and safety of natalizumab in Finnish multiple sclerosis patients (2023)
- Multiple Sclerosis Journal - Experimental, Translational and Clinical
- The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis (2023)
- Current Medical Research and Opinion
- Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study (2022)
- Multiple Sclerosis and Related Disorders
- Miksi MS-tauti yleistyy? (2022)
- Duodecim
- MS-taudin ja liikehäiriöiden laaturekisterit (2022)
- Erikoislääkäri
- Neurosarkoidoosin uudistunut diagnostiikka ja tehostunut hoito (2021)
- Duodecim
- Alemtuzumab is a budget-saving alternative to fingolimod and natalizumab in the treatment of highly active relapsing-remitting multiple sclerosis (2020)
- Dosis
- Changes in multiple sclerosis epidemiology in Finland over five decades (2020)
- Acta Neurologica Scandinavica
- Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients (2020)
- Journal of Neuroimmune Pharmacology
UTU Research Portal